{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:16:49Z","timestamp":1790806609223,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.amjmed.2025.11.025","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:01:16Z","timestamp":1764259276000},"page":"264-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in neurological therapies: A review of clinical trials in Alzheimer\u2019s, Parkinson\u2019s, and multiple sclerosis"],"prefix":"10.1016","volume":"139","author":[{"given":"Pedro C\u00e9sar","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaynara Paula Warren","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moacyr Jesus Barreto","family":"de Melo R\u00eago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-3833","authenticated-orcid":false,"given":"Michelle Melgarejo","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2025.11.025_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-031-75980-2_3","article-title":"Epigenetics in Neurodegenerative Diseases","volume":"108","author":"van Zundert","year":"2025","journal-title":"Subcell Biochem"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/WCO.0000000000001356","article-title":"Neuroinflammation and immunometabolism in neurodegenerative diseases","volume":"38","author":"Lonkar","year":"2025","journal-title":"Curr Opin Neurol"},{"issue":"18","key":"10.1016\/j.amjmed.2025.11.025_bib0003","doi-asserted-by":"crossref","first-page":"9947","DOI":"10.3390\/ijms25189947","article-title":"Significance of Programmed Cell Death Pathways in Neurodegenerative Diseases","volume":"25","author":"Guo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0004","unstructured":"Synthesis reference: ALZHEIMER'S DISEASE INTERNATIONAL. World Alzheimer Report 2024: Global changes in attitudes to dementia. Available at: <https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2024\/>. Accessed: 06\/15\/25."},{"issue":"10","key":"10.1016\/j.amjmed.2025.11.025_bib0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol."},{"issue":"21","key":"10.1016\/j.amjmed.2025.11.025_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111334","article-title":"Neurodegenerative Diseases: Molecular Mechanisms and Therapies 2nd Edition","volume":"25","author":"Zhou","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00401-025-02868-5","article-title":"Impaired remyelination in late-onset multiple sclerosis","volume":"149","author":"Stork","year":"2025","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0008","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41392-025-02145-7","article-title":"Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances","volume":"10","author":"Jiang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.amjmed.2025.11.025_bib0009","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.3390\/ijms26115177","article-title":"The Role of Inflammation in Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis","volume":"26","author":"Fo\u0142ta","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.amjmed.2025.11.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70176","article-title":"Alzheimer's Disease: Treatment Challenges for the Future","volume":"169","author":"Hardy","year":"2025","journal-title":"J Neurochem"},{"issue":"21","key":"10.1016\/j.amjmed.2025.11.025_bib0011","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1021\/acschemneuro.4c00339","article-title":"Alzheimer's Disease: Exploring the Landscape of Cognitive Decline","volume":"15","author":"Tenchov","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"10.1016\/j.amjmed.2025.11.025_bib0012","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00702-024-02813-y","article-title":"Neuroplasticity in Parkinson's disease","volume":"131","author":"Popescu","year":"2024","journal-title":"J Neural Transm"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2024.12.003","article-title":"Pathogenesis of Parkinson's Disease","volume":"43","author":"Xiao","year":"2025","journal-title":"Neurol Clin"},{"issue":"5","key":"10.1016\/j.amjmed.2025.11.025_bib0014","first-page":"448","article-title":"[Parkinson's Disease]","volume":"77","author":"Funayama","year":"2025","journal-title":"Brain Nerve"},{"issue":"6","key":"10.1016\/j.amjmed.2025.11.025_bib0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/imj.70023","article-title":"Advancements in multiple sclerosis","volume":"55","author":"Montague","year":"2025","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.amjmed.2025.11.025_bib0016","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","article-title":"Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects","volume":"76","author":"Olejnik","year":"2024","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2025.11.025_bib0018","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2025.11.025_bib0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neurol.2025.03.008","article-title":"Multiple sclerosis and epilepsy","volume":"181","author":"Catenoix","year":"2025","journal-title":"Rev Neurol"},{"issue":"6","key":"10.1016\/j.amjmed.2025.11.025_bib0020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/08919887241248831","article-title":"Parkinson's Disease: Coping Strategies, Cognitive Restructuring and Deep Brain Stimulation","volume":"37","author":"Meyer","year":"2024","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ncl.2024.12.009","article-title":"Disease-Modifying Therapies in Parkinson's Disease","volume":"43","author":"Fabbri","year":"2025","journal-title":"Neurol Clin"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ncl.2024.12.005","article-title":"Biomarkers in Parkinson's Disease","volume":"43","author":"Brooker","year":"2025","journal-title":"Neurol Clin"},{"issue":"4","key":"10.1016\/j.amjmed.2025.11.025_bib0023","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ncl.2024.05.010","article-title":"Neuropsychological Manifestations of Multiple Sclerosis","volume":"42","author":"Hancock","year":"2024","journal-title":"Neurol Clin"},{"issue":"19","key":"10.1016\/j.amjmed.2025.11.025_bib0024","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/j.neuron.2024.05.025","article-title":"Neurodegeneration and demyelination in multiple sclerosis","volume":"112","author":"Garton","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111715","article-title":"Neurodegenerative diseases: Epigenetic regulatory mechanisms and therapeutic potential","volume":"131","author":"Men","year":"2025","journal-title":"Cell Signal"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102488","article-title":"Neuroenergetic alterations in neurodegenerative diseases: A systematic review and meta-analysis of in vivo31P-MRS studies","volume":"101","author":"Jing","year":"2024","journal-title":"Ageing Res Rev"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0027","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pathol.2024.10.006","article-title":"Current concepts and molecular pathology of neurodegenerative diseases","volume":"57","author":"Forrest","year":"2025","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0028","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5603\/pjnns.103572","article-title":"Do Parkinson's Disease clinical subtypes really exist?","volume":"59","author":"Filidei","year":"2025","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0029","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2025","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40035-024-00447-4","article-title":"Cellular senescence in Alzheimer's disease: from physiology to pathology","volume":"13","author":"Zhu","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"3","key":"10.1016\/j.amjmed.2025.11.025_bib0031","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41593-025-01873-x","article-title":"Oligodendrocytes in Alzheimer's disease pathophysiology","volume":"28","author":"Kedia","year":"2025","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.amjmed.2025.11.025_bib0032","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.3390\/ijms26104860","article-title":"Therapeutic Mechanisms of Exercise in Parkinson's Disease","volume":"26","author":"Wilson","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107208","article-title":"Parkinson's disease subtypes: Approaches and clinical implications","volume":"130","author":"Deng","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1877718X241304814","article-title":"Rethinking 'rare' PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and \u03b1-synuclein pathology","volume":"15","author":"Yin","year":"2025","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.amjmed.2025.11.025_bib0037","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1007\/s12035-025-04788-7","article-title":"Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges","volume":"62","author":"Almasi","year":"2025","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155985","article-title":"The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes","volume":"270","author":"Chen","year":"2025","journal-title":"Pathol Res Pract"},{"issue":"10","key":"10.1016\/j.amjmed.2025.11.025_bib0039","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1474-4422(24)00256-4","article-title":"Differential diagnosis of suspected multiple sclerosis: global health considerations","volume":"23","author":"Correale","year":"2024","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.amjmed.2025.11.025_bib0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/WCO.0000000000001369","article-title":"Re-defining progression in multiple sclerosis","volume":"38","author":"Lambe","year":"2025","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.amjmed.2025.11.025_bib0041","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA."},{"issue":"12","key":"10.1016\/j.amjmed.2025.11.025_bib0042","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2025.11.025_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001694","article-title":"If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?","volume":"20","author":"Haass","year":"2022","journal-title":"PLoS Biol"},{"issue":"17","key":"10.1016\/j.amjmed.2025.11.025_bib0044","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/diagnostics15172158","article-title":"Early Detection of Cognitive Decline: Executive Functioning Index R4Alz-pc Predicts Memory-Related Concerns in Community Adults","volume":"15","author":"Emmanouilidou","year":"2025","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.amjmed.2025.11.025_bib0045","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0046","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-020-00678-3","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer's dementia","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0047","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2024.12.003","article-title":"Pathogenesis of Parkinson's Disease","volume":"43","author":"Xiao","year":"2025","journal-title":"Neurol Clin"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0048","article-title":"O processo de angiog\u00eanese na neurodegenera\u00e7\u00e3o \u2014 patomecanismos e novas interven\u00e7\u00f5es terap\u00eauticas","author":"Kieliszek-Ryba","year":"2025","journal-title":"Psicofarmacologia"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0049","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43096-9","article-title":"MicroRNAs in Parkinson\u2019s disease: a systematic review and diagnostic accuracy meta-analysis","volume":"13","author":"Gu\u00e9vremont","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.amjmed.2025.11.025_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100205","article-title":"for Alzheimer\u2019s Disease Neuroimaging Initiative. Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease","volume":"12","author":"Abbas","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.amjmed.2025.11.025_bib0052","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"3","key":"10.1016\/j.amjmed.2025.11.025_bib0053","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/13872877251319048","article-title":"Compostos bioativos e padr\u00f5es alimentares na doen\u00e7a de Alzheimer","volume":"104","author":"Christimann","year":"2025","journal-title":"J Alzheimer's Disease"},{"issue":"13","key":"10.1016\/j.amjmed.2025.11.025_bib0054","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson's Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41531-025-01041-9","article-title":"Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson\u2019s disease trials","volume":"11","author":"Pagano","year":"2025","journal-title":"npj Parkinsons Dis"},{"issue":"7","key":"10.1016\/j.amjmed.2025.11.025_bib0056","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A Phase 1B Trial in GBA1 - Associated Parkinson\u2019s Disease of BIA-28-6156, a Glucocerebrosidase Activator","volume":"38","author":"Den Heijer","year":"2023","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1016\/j.amjmed.2025.11.025_bib0057","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson\u2019s Disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0058","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s42004-025-01558-3","article-title":"A mechanistic model of pure and lipidic \u03b1-synuclein aggregation for advancing Parkinson\u2019s therapies","volume":"8","author":"Righetti","year":"2025","journal-title":"Commun Chem"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0059","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41467-023-37464-2","article-title":"Disrupting the \u03b1-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson\u2019s disease","volume":"14","author":"Nim","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41531-025-01080-2","article-title":"Impact of \u03b1-synuclein fibril structure on seeding activity in experimental models of Parkinson\u2019s disease","volume":"11","author":"Ohira","year":"2025","journal-title":"npj Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0061","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1038\/s41467-025-63025-w","article-title":"Integrating artificial intelligence and optogenetics for Parkinson\u2019s disease diagnosis and therapeutics in male mice","volume":"16","author":"Hyeon","year":"2025","journal-title":"Nat Commun"},{"issue":"8064","key":"10.1016\/j.amjmed.2025.11.025_bib0062","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","article-title":"Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease","volume":"641","author":"Sawamoto","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0063","article-title":"The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson\u2019s disease","volume":"15","author":"He","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0064","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16055","article-title":"Home-based exergaming to treat gait and balance disorders in patients with Parkinson\u2019s disease: A phase II randomized controlled trial","volume":"31","author":"Nuic","year":"2024","journal-title":"Euro J of Neurology"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43096-9","article-title":"MicroRNAs in Parkinson\u2019s disease: a systematic review and diagnostic accuracy meta-analysis","volume":"13","author":"Gu\u00e9vremont","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0066","doi-asserted-by":"crossref","DOI":"10.1101\/2024.12.13.24318996","article-title":"Prioritizing Parkinson\u2019s disease risk genes in genome-wide association loci [Internet]","author":"Lange","year":"2024","journal-title":"Genetic and Genomic Med"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0067","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41531-025-01041-9","article-title":"Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson\u2019s disease trials","volume":"11","author":"Pagano","year":"2025","journal-title":"npj Parkinsons Dis"},{"issue":"12","key":"10.1016\/j.amjmed.2025.11.025_bib0068","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41582-024-01023-0","article-title":"Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis","volume":"20","author":"Kalia","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0069","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1038\/s41598-025-94148-1","article-title":"Preclinical assessment of a ganglioside-targeted therapy for Parkinson\u2019s disease with the first-in-class adaptive peptide AmyP53","volume":"15","author":"Fantini","year":"2025","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.amjmed.2025.11.025_bib0070","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1007\/s12035-025-04788-7","article-title":"Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges","volume":"62","author":"Almasi","year":"2025","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102816","article-title":"Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis","volume":"50","author":"Naseri","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"10","key":"10.1016\/j.amjmed.2025.11.025_bib0072","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult Scler"},{"issue":"13","key":"10.1016\/j.amjmed.2025.11.025_bib0073","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.3390\/nu15132861","article-title":"Effect of Vitamin D Supplementation on Fatigue in Multiple Sclerosis: A Systematic Review and Meta-Analysis","volume":"15","author":"L\u00f3pez-Mu\u00f1oz","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0074","article-title":"The association between vitamin D deficiency and multiple sclerosis: an updated systematic review and meta-analysis","volume":"90","author":"Balasooriya","year":"2024","journal-title":"Mult Scleros Related Disorders"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105721","article-title":"Faecal mucoprotein MUC2 is decreased in multiple sclerosis and is associated with mucin degrading bacteria","volume":"116","author":"Schwerdtfeger","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0076","article-title":"High-intensity resistance training in people with multiple sclerosis experiencing fatigue: A randomised controlled trial","volume":"68","author":"Englund","year":"2022","journal-title":"Mult Scleros Related Disorders"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0077","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0078","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrneurol.2010.179","article-title":"The emerging role of microRNAs in multiple sclerosis","volume":"7","author":"Junker","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.amjmed.2025.11.025_bib0079","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrneurol.2010.198","article-title":"Therapies for multiple sclerosis: considerations in the pediatric patient","volume":"7","author":"Banwell","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.amjmed.2025.11.025_bib0080","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2025.11.025_bib0083","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/alz.12172","article-title":"36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer\u2019s disease","volume":"17","author":"Soininen","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105291","article-title":"Alzheimer\u2019s disease biomarkers and the tyranny of treatment","author":"Karlawish","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.amjmed.2025.11.025_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155985","article-title":"The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes","volume":"270","author":"Chen","year":"2025","journal-title":"Pathol Res Pract"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325008265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325008265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:37:30Z","timestamp":1771216650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325008265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0002934325008265"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.11.025","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in neurological therapies: A review of clinical trials in Alzheimer\u2019s, Parkinson\u2019s, and multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}